KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash from Operations (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Cash from Operations for 18 consecutive years, with 792819000.0 as the latest value for Q1 2026.

  • For Q1 2026, Cash from Operations fell 425.83% year-over-year to 792819000.0; the TTM value through Mar 2026 reached 910627000.0, down 81.48%, while the annual FY2025 figure was 268583000.0, 46.38% up from the prior year.
  • Cash from Operations hit 792819000.0 in Q1 2026 for Ionis Pharmaceuticals, down from 137709000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 151338000.0 in Q2 2025 and bottomed at 792819000.0 in Q1 2026.
  • Average Cash from Operations over 5 years is 126131294.12, with a median of 116139000.0 recorded in 2024.
  • Year-over-year, Cash from Operations tumbled 453.38% in 2024 and then soared 226.24% in 2025.
  • Ionis Pharmaceuticals' Cash from Operations stood at 200195000.0 in 2022, then skyrocketed by 116.42% to 32865000.0 in 2023, then crashed by 453.38% to 116139000.0 in 2024, then decreased by 18.57% to 137709000.0 in 2025, then plummeted by 475.72% to 792819000.0 in 2026.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 792819000.0, 137709000.0, and 131437000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.